GC
KDNY

Globeflex Capital’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Globeflex Capital’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-7,240
Closed -$413K – 565
2016
Q4 		$413K Sell
7,240
-1,660
-19% -$100K 0.1% 284
2016
Q3 		$553K Sell
8,900
-20
-0.2% -$1.41K 0.14% 235
2016
Q2 		$504K Hold
8,920
– – 0.14% 238
2016
Q1 		$571K Buy
8,920
+2,840
+47% +$230K 0.15% 212
2015
Q4 		$855K Buy
6,080
+3,040
+100% +$413K 0.23% 173
2015
Q3 		$294K Buy
+3,040
New +$362K 0.06% 338

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Globeflex Capital's KDNY Position: Q1 2017 in Review

Globeflex Capital sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2017, closing a stake of 7,240 shares — an estimated $413K sold.

Globeflex Capital first reported a position in KDNY in Q3 2015 and held it in 6 quarters. The position peaked at $855K in Q4 2015. 82 funds tracked by Wall St. Rank hold KDNY as of Q1 2017.

  • Globeflex Capital reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Globeflex Capital sold 7,240 Chinook Therapeutics, Inc. Common Stock shares in Q1 2017, an estimated $413K.
  • Globeflex Capital first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2015 and held it in 6 quarters.
  • Globeflex Capital's Chinook Therapeutics, Inc. Common Stock position peaked at $855K in Q4 2015.
  • 82 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2017.

Based on Globeflex Capital's 13F filing for Q1 2017, filed 12 May 2017.